Modelled policy outcomes, with posterior values for individual nodes ranked from 1-5 across the parties - Green, Reform UK, Liberal Democrat, Conservative, and Labour, where 1 is the lowest rank and 5 is the highest. The parties are ranked for each policy node in the network (e.g., income tax), based on the direction of change (“performance indicator”) stated in the first column (e.g., lowest, highest, most, improvement). For example, a value of 5 for Green tax means that green tax is lowest under Reform UK’s policies, while a value of 1 means that green tax is highest under the Green Party’s policies.... by Richard Stafford (174326)

“…The parties are ranked for each policy node in the network (e.g., income tax), based on the direction of change (“performance indicator”) stated in the first column (e.g., lowest, highest, most, improvement). For example, a value of 5 for Green tax means that green tax is lowest under Reform UK’s policies, while a value of 1 means that green tax is highest under the Green Party’s policies. …”

Decreased expression of TCA cycle and ETC enzymes in kidneys from rats administered Tl. by Sho Sugahara (11895828)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Wnt signaling decreases the recruitment of RAB8a to basal bodies. by Cheng Yuan (160315)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Pregnancy-induced decrease in maternal serum BUN and IFN- by Haruka Mizobuchi (5395394)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Figure 5 from Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin by Joanna Domagala (21643925)

“…<b>J,</b> Processing of perforin by human recombinant granzyme B at concentrations of 0.5, 1, and 2.5 μmol/L, assessed at pH 7.4 in two different buffers (<i>n</i> = 2). …”

Study 1_CFA1. by Chen-Yueh Chen (9740047)

“…<div><p>The purposes of this paper are to develop measurement scale of value co-creation among spectators in professional spectating sporting events by means of Study I and to examine the effects of social media strategies on value co-creation among spectators through Study II. …”

TITAN thresholds and percentile estimates for benthic macroinvertebrate and diatom communities deemed to be sensitive decreasers or tolerant increasers. The thresholds represent the largest fsum <i>z</i> value in the main data analysis run (i.e., the median), whereas the 5^th and 95^th percentile change points are determined from 500 bootstrap replicate runs. Sensitive taxa change points derived from decreaser sum <i>z</i>- relative to increasing impervious cover (I.C.; %), specific conductivity (SpCond; μS cm^-1), total nitrogen (TN; μg L^-1), and total phosphorus (TP; μg L^-1).... by Brent J. Bellinger (21156150)

“…Sensitive taxa change points derived from decreaser sum <i>z</i>- relative to increasing impervious cover (I.C.; %), specific conductivity (SpCond; μS cm^-1), total nitrogen (TN; μg L^-1), and total phosphorus (TP; μg L^-1). …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Median EQ-5D-3L index values during 5 years of follow-up. by Karl Ingard (22582091)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: